@article{d52862ca568f4f24a174e621c61b82c8,
title = "Industry updates from the field of stem cell research and regenerative medicine in March 2022",
keywords = "industry, regenerative medicine, stem cells",
author = "Dusko Ilic and Mirjana Liovic",
note = "Funding Information: NexoBrid, MediWound{\textquoteright}s commercial orphan biological product for non surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within 4 h without harming surrounding viable tissue. NexoBrid is currently marketed in the EU and other international markets and is at registration-stage in the US. NexoBrid is supported by the US Biomedical Advanced Research and Development Authority (BARDA), office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services. EscharEx{\textcopyright}R, MediWound{\textquoteright}s next-generation bioactive topical therapeutic under development in the USA for debridement of chronic and hard to heal wounds. In two phase II studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.",
year = "2022",
month = jul,
doi = "10.2217/rme-2022-0073",
language = "English",
volume = "17",
pages = "419--426",
journal = "Regenerative medicine",
issn = "1746-0751",
publisher = "Future Medicine",
number = "7",
}